New Covid-19 clusters in urban India raise alarms: Doctor reveals 7 categories of people at higher coronavirus risk
While the masks may be off and travel plans thriving amid summer break, Covid-19 is quietly reminding us that it hasn't vanished. As of Tuesday morning, India reported 6,815 active Covid-19 cases, with 324 fresh cases in just the last 24 hours, according to the Ministry of Health and Family Welfare (MoHFW).
Although these numbers are far from the alarming peaks of earlier waves, they hint at a subtle resurgence that deserves attention, not panic. Among the newly reported cases, three Covid-related deaths were recorded: one each from Delhi, Kerala and Jharkhand.
In an interview with HT Lifestyle, Dr Preeti Kabra shared, 'As of now, India is not witnessing a significant surge but sporadic cases are emerging across states and localised clusters especially in urban population are being monitored. One of the challenges is that many people with mild symptoms are not testing, so true case numbers may be underreported.'
She added, 'What's encouraging, however, is that hospitalisation and death rates remain low a sign that vaccinations and past exposures continue to provide some level of protection.'
From a clinical standpoint, Dr Preeti Kabra asserted that the following groups must exercise extra caution:
These individuals are more likely to develop complications like pneumonia, clotting disorders, or long Covid, even if the current strains appear milder.
Dr Preeti Kabra answered, 'Vaccination especially when up to date with boosters still offers strong protection against severe disease and death. That said, breakthrough infections are common due to waning antibodies, but these cases are often milder and resolve faster.'
Vaccinated individuals may still get infected, but tend to recover at home with minimal symptoms. Dr Preeti Kabra cautioned, 'However, they can still transmit the virus. Unvaccinated individuals are at greater risk of complications and longer illness durations. The absence of immunity also makes them more vulnerable to newer variants.'
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
35 minutes ago
- Deccan Herald
Covid cases in Karnataka crosses 1,550
There are now 395 active cases of Covid and a cumulative of 1,555 Covid positive cases recorded in the state since January 1.
Time of India
39 minutes ago
- Time of India
Sedentary lifestyle leads to rise in non-alcoholic fatty liver disease among young adults
Bengaluru: At first glance, most people wouldn't think twice about fatigue, occasional discomfort or a slightly abnormal report during routine a check-up. However, doctors in Bengaluru say these signals are now linked to something more serious: fatty liver disease, specifically, non-alcoholic fatty liver disease (NAFLD). Since Covid-19 pandemic, city hospitals reported a 30% increase in NAFLD cases, with a noticeable surge among young adults in their 20s and 30s. Unlike traditional liver disease linked to alcohol use, this condition stems from poor lifestyle, long hours of desk work, processed food, irregular meals and physical inactivity. Dr Santhosh Kumar S C, consultant, gastroenterology at Fortis Hospital, said, "We're seeing a sharp rise in non-alcoholic fatty liver disease, with over 10 patients on average per day. The main reason: Obesity." He said NAFLD cases are being observed across socio-economic groups. A person sitting at a paan stall all day, an autorickshaw or cab driver, anyone with a sedentary lifestyle is vulnerable. There are two broad types of fatty liver - alcoholic and non-alcoholic. While alcoholic fatty liver was more common earlier, now people with no or limited alcohol use are being diagnosed due to carb-heavy diets, inactivity, and prolonged sitting, he explained. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Perdagangkan CFD Emas dengan Broker Tepercaya IC Markets Mendaftar Undo Dr Harshavardhan Rao B, head of department and consultant, medical gastroenterology, Ramaiah Memorial Hospital, said, "Fatty liver isn't just about fat, it's a warning sign for your metabolism. It's now called metabolic dysfunction-associated fatty liver disease or MAFLD because it reflects the combined impact of diabetes, hypertension, obesity, abnormal cholesterol, poor diet, lack of physical activity, and even stress. " He noted a clear shift after the pandemic. "Many switched to a sedentary work-from-home lifestyle, relied on outside food, and faced longer working hours, all of which pushed physical and mental health to the back seat. As a result, we're seeing more people diagnosed incidentally with fatty liver on routine scans." MAFLD often progresses in stages, beginning with fat accumulation, followed by inflammation, and then, in some cases, fibrosis, cirrhosis, or even cancer. Many patients show no symptoms until liver damage is already underway, highlighted Dr Rao. However, the condition is often reversible in its early stages. Changes in diet, increased physical activity, regular sleep, and health checks can prevent progression. Dr Vinay Kumar B R, hepatologist and liver transplantation specialist, Narayana Health City, said, "In Bengaluru, especially among IT professionals and those with desk jobs, we see a significant rise in both diabetes and fatty liver. It's now common to find some degree of fatty liver in two to three out of every five patients during routine scans or blood tests." Dr Balaji Gurrappa, consultant, gastroenterology, Kauvery Hospital, added, "In women, Polycystic Ovarian Disease (PCOD) and use of hormonal pills can also increase risk." BOX: Precautions Maintain healthy weight Embrace balanced diet Stay physically active Manage underlying health conditions Limit or avoid alcohol BOX: Risk factors Diabetes Hypertension Cholesterol Obesity Poor lifestyle Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus
German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the agreed deal, which pairs two former rivals in the race to develop COVID-19 vaccines, each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, BioNTech said. The deal further underscores BioNTech's costly long-term ambition to focus on new cancer treatments and show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine development to its alliance partner, Britain's GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. BioNTech last week won a major shot in the arm for its cancer drug activities when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda. The company said payment in BioNTech shares would be subject to a collar mechanism - if the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. CureVac shareholders are expected to own between 4% and 6% of BioNTech after the deal closes, it added.
